Fluoroquinolone Toxicity and FQAD

An evidence brief for prescribers — mechanism, clinical picture, and the informed-consent gap

FQAD is often met with skepticism because symptoms may cross systems, begin after the drug is stopped, and appear despite a normal routine exam. This brief explains why the syndrome is biologically coherent, what it looks like clinically, where the evidence is strongest, and why informed consent is foundational to surveillance.

1. A coherent, multi-target pharmacology

FQAD is not a diagnosis of exclusion or a psychosomatic label. Fluoroquinolones act on identifiable human targets, producing a multi-system picture. When exposure history is missed, delayed onset and a normal exam can lead to misdiagnosis as anxiety, fibromyalgia, CFS, neuropathy, autoimmune disease, medication intolerance, or aging — especially when FQ injury is dismissed as "too rare."

Mitochondrial injury (the best-established axis). In mammalian cells, bactericidal antibiotics including fluoroquinolones drive mitochondrial dysfunction and reactive-oxygen-species overproduction, with oxidative damage to DNA, protein, and lipid (Kalghatgi et al., 2013). Mechanistically, ciprofloxacin inhibits mitochondrial topoisomerase 2 (Top2β), which maintains mitochondrial-DNA supercoiling, impairing mtDNA replication and transcription (Hangas et al., 2018). Chemical-proteomic mapping has since identified direct human off-targets of ciprofloxacin, among them AIFM1 and IDH2 (Reinhardt et al., 2025). Because mitochondria power the most energy-demanding tissues, this axis fits the observed pattern — tendon, nerve, muscle, and CNS.

Neuro-excitatory effects. Fluoroquinolones are selective antagonists of the GABA-A receptor (Halliwell et al., 1997), lowering the brain's principal inhibitory tone, and they facilitate NMDA-receptor activity — in part by chelating the magnesium that normally gates it. This is the accepted basis for their seizure risk and a plausible contributor to the neuropsychiatric features.

Connective-tissue effects. In tendon cells and chondrocytes, fluoroquinolones generate oxidative stress and disturb the collagen/matrix balance — consistent with the tendinopathy that first drove the 2008 boxed warning.

The structural point that matters clinically. Different parts of the molecule govern different toxicities: the C7 ring drives GABA-A antagonism, the β-keto-acid / magnesium-chelation motif drives topoisomerase poisoning, and the C6 fluorine functions mainly as a potency-and-tissue-penetration feature — not the toxic core. The implication is that **mechanism, not the mere presence of a fluorine atom, is the meaningful axis of risk**.

2. Why it can persist — a proposed model, honestly graded

The hardest question is why some patients recover and others do not. What follows is an integrative model; its parts carry different levels of evidence, and it is worth being explicit about which. Picture mitochondrial health as a *running balance* between damage and clearance:

Act 1 — the first hit. Top2β poisoning, magnesium chelation, ROS, and GABA-A interference tip the balance toward mitochondrial, connective-tissue, and neuro-excitatory injury. *Evidence: well-established in human cells and consistent with known fluoroquinolone CNS warnings.*

Act 2 — propagation. A replicative bias (the ATFS-1 / POLG loop) can keep adding damaged mtDNA copies rather than clearing them. *Evidence: demonstrated in C. elegans, human cybrid support; the human propagation role is inferred, not yet shown.*

Act 3 — clearance failure. Mitophagy (PINK1 / Parkin) should remove damaged mitochondria but can be outpaced, tissue-limited, or threshold-evading. *Evidence: the machinery is established; the fluoroquinolone-specific overlay is inferred.*

Whether a patient recovers or persists becomes a question of which force wins. Stated this way — with the confidence gradient visible — the model explains the tissue-selective persistence seen in tendon, muscle, and nerve without overclaiming.

Act	What it proposes	Evidence status
1	First hit — Top2β poisoning, Mg^{2+} chelation, ROS	Well-established in human cells
2	Propagation — replicative bias adds damaged mtDNA copies	Worm-demonstrated; human cybrid support;

Act	What it proposes	Evidence status
		human role inferred
3	Clearance failure — mitophagy outpaced or tissue-limited	Machinery established; FQ overlay inferred

3. The clinical picture

A 2015 BMJ case series described four previously healthy, employed adults who developed a severe, disabling, multi-system syndrome during fluoroquinolone use that progressed after discontinuation — spanning tendinopathy, muscle weakness, peripheral neuropathy, autonomic dysfunction, sleep disturbance, cognitive dysfunction, and psychiatric symptoms (Golomb et al., 2015). That profile — delayed, multi-system, persistent, in someone who looks well — is exactly what makes FQAD easy to miss and easy to misattribute. Formal diagnostic criteria now exist (Pieper, Springer, 2nd ed., 2026), and the injury is codeable in ICD-10-CM as of October 2025 (T36.AX5A / -D / -S, adverse effect of fluoroquinolone antibiotics).

4. The surveillance gap

Recognition depends on a system that can see, and three gaps limit that. Spontaneous reporting (FAERS) captures only a fraction of events and is poorly suited to reactions that begin weeks after a short course. There is no longitudinal cohort or natural-history study to establish relapse rates, recovery trajectories, or the factors that separate the two. And there is no established patient registry. The result is a syndrome the FDA has formally acknowledged yet cannot quantify.

5. Informed consent as the foundational pharmacovigilance step

Here the argument turns practical. Informed consent is usually treated as a downstream ethics formality. In pharmacovigilance it is the opposite — it is the **upstream input the whole system depends on**. A patient told, at the moment of prescribing, what to watch for can recognize an early sign, seek timely care, and report; a patient not told cannot, and the surveillance system is blind at its source. This reframes the prescriber not as a point of liability but as the front line of detection.

The petition asks, in essence: if the FDA has acknowledged disabling and potentially permanent fluoroquinolone-associated effects, why are patients not routinely informed before exposure in a way that supports recognition, reporting, and timely care? (FDA Citizen Petition, Docket FDA-2026-P-5116.)

The clinical takeaway is small and within every prescriber's control: a brief, specific conversation at the point of prescribing. In the case narratives behind this work, the recurring pivot was not a treatment — it was information. **What changed was information.**

References

1. Kalghatgi S, Spina CS, Costello JC, et al. Bactericidal antibiotics induce mitochondrial dysfunction and oxidative damage in mammalian cells. *Sci Transl Med*. 2013;5(192):192ra85.
2. Hangas A, Aasumets K, Kekäläinen NJ, et al. Ciprofloxacin impairs mitochondrial DNA replication initiation through inhibition of Topoisomerase 2. *Nucleic Acids Res*. 2018;46(18):9625–9636.
3. Reinhardt T, El Harraoui Y, Rothemann A, et al. Chemical proteomics reveals human off-targets of fluoroquinolone-induced mitochondrial toxicity. *Angew Chem Int Ed Engl*. 2025;64(18):e202421424.
4. Yang et al. LONP-1 and ATFS-1 sustain deleterious heteroplasmy by promoting mtDNA replication in dysfunctional mitochondria. *Nat Cell Biol. 2022.*
5. Halliwell RF, Davey PG, Lambert JJ. Selective antagonism of the GABA-A receptor by ciprofloxacin and biphenylacetic acid. *Br J Pharmacol*. 1997;122:584–590.
6. Golomb BA, Koslik HJ, Redd AJ. Fluoroquinolone-induced serious, persistent, multisymptom adverse effects. *BMJ Case Rep*. 2015;2015: bcr2015209821.
7. Pieper S. *Fluoroquinolone-Associated Disability FQAD: Side-effects of Fluoroquinolones.* 2nd ed. Springer; 2026.
8. U.S. Food and Drug Administration. Drug Safety Communications on fluoroquinolones, 2008–2018.

Learn more

Fluoroquinolone Toxicity Study, NFP (**fq100.org**) · DIMD Initiative (**druginducedmito.org**; framework at Zenodo DOI 10.5281/zenodo.20399689).

Compiled by Johanna Ihli, BSN — former critical-care RN, DIMD Initiative. Educational context on mechanism, evidence, and diagnosis; not individualized treatment advice.

fq100.org **druginducedmito.org**